Tildrakizumab not checked

Sun Pharma · SCH 900222 · MK-3222

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
6 active
11 in total · 7 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter”In the company’s words, NCT06611163 on ClinicalTrials.gov
Tested for
Active Psoriatic Arthritis, Moderate to Severe Genital Psoriasis, Psoriatic Arthritis, Moderate-to-severe Chronic Plaque Psoriasis
Main trialPhase 3
“This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .”In the company’s words, NCT04314531 on ClinicalTrials.gov
Other names
SCH 900222 · MK-3222 · TILD · TILD sub-cutaneous

Other drugs for Active Psoriatic Arthritis

All 29 drugs for Active Psoriatic Arthritis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 4 Jun 2025 Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Phase 3Active, not recruiting 21 Jan 2026 A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Phase 3Active, not recruiting Dec 2028 Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Phase 2/3Active, not recruiting 7 Apr 2025 A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
Phase 3Completed 28 Sep 2015 A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
Phase 3Completed 28 Oct 2015 A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
Phase 3Withdrawn Aug 2018 A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
Phase 3Completed 5 Apr 2024 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3Completed 26 Mar 2025 Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Phase 2Authorised not given Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
Phase 2Authorised not given Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tildrakizumab

Following is part of Solo: you see every change to Tildrakizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in